Jul 13, 2012 - 6:06 pm
Has any one heard of or have an opinion on the Nymox's U.S. Phase 2 Clinical Trial of NX-1207 for localized T1c prostate cancer ? It's an intraprostatic injection of NX-1207 of 0 ( control), 2.5 or 10 mg and f/u over various time intervals. It's an NCI sponsored Study recruiting patients who are currently on AS. I believe the NX 1207 must belong to the family of 5 alpha reductase inhibitors ( Avodart, Proscar etc)or a close analog.